Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.

Emadi A, Law JY, Strovel ET, Lapidus RG, Jeng LJB, Lee M, Blitzer MG, Carter-Cooper BA, Sewell D, Van Der Merwe I, Philip S, Imran M, Yu SL, Li H, Amrein PC, Duong VH, Sausville EA, Baer MR, Fathi AT, Singh Z, Bentzen SM.

Cancer Chemother Pharmacol. 2018 Jan;81(1):217-222. doi: 10.1007/s00280-017-3459-6. Epub 2017 Nov 8.

PMID:
29119293
2.

Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia.

Koka R, Bade NA, Sausville EA, Ning Y, Zou Y.

Mol Cytogenet. 2017 Oct 26;10:39. doi: 10.1186/s13039-017-0340-6. eCollection 2017.

3.

Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells.

Carter-Cooper BA, Fletcher S, Ferraris D, Choi EY, Kronfli D, Dash S, Truong P, Sausville EA, Lapidus RG, Emadi A.

Bioorg Med Chem Lett. 2017 Jan 1;27(1):6-10. doi: 10.1016/j.bmcl.2016.11.045. Epub 2016 Nov 17.

4.

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.

Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A.

Appl Immunohistochem Mol Morphol. 2017 May/Jun;25(5):334-337. doi: 10.1097/PAI.0000000000000342. Review.

PMID:
26945443
5.

Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.

Schwartz GK, Dickson MA, LoRusso PM, Sausville EA, Maekawa Y, Watanabe Y, Kashima N, Nakashima D, Akinaga S.

Cancer Sci. 2016 Apr;107(4):499-506. doi: 10.1111/cas.12906. Epub 2016 Mar 28.

6.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

7.

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP.

Bone Marrow Transplant. 2016 Jun;51(6):850-2. doi: 10.1038/bmt.2015.346. Epub 2016 Feb 1. No abstract available.

PMID:
26828905
8.

A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone.

Pidugu LS, Mbimba JC, Ahmad M, Pozharski E, Sausville EA, Emadi A, Toth EA.

BMC Struct Biol. 2016 Jan 28;16:1. doi: 10.1186/s12900-016-0052-x.

9.

Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2.

Lapidus RG, Carter-Cooper BA, Sadowska M, Choi EY, Wonodi O, Muvarak N, Natarajan K, Pidugu LS, Jaiswal A, Toth EA, Rassool FV, Etemadi A, Sausville EA, Baer MR, Emadi A.

Pharmaceuticals (Basel). 2016 Jan 19;9(1). pii: E4. doi: 10.3390/ph9010004.

10.

Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.

Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG.

Leuk Res. 2015 Jul;39(7):719-29. doi: 10.1016/j.leukres.2015.04.002. Epub 2015 Apr 30.

PMID:
25982179
11.

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.

LoRusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA.

Invest New Drugs. 2015 Apr;33(2):440-9. doi: 10.1007/s10637-015-0211-0. Epub 2015 Feb 17.

PMID:
25684345
12.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.

13.

Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation.

Oliver N, Short B, Thein M, Duong VH, Tidwell ML, Sausville EA, Baer MR, Kamangar F, Emadi A.

Leuk Lymphoma. 2015 Jul;56(7):2082-6. doi: 10.3109/10428194.2014.982640. Epub 2015 Jan 14.

PMID:
25379622
14.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.

PMID:
25183650
15.

Asparaginase in the treatment of non-ALL hematologic malignancies.

Emadi A, Zokaee H, Sausville EA.

Cancer Chemother Pharmacol. 2014 May;73(5):875-83. doi: 10.1007/s00280-014-2402-3. Epub 2014 Feb 11. Review.

PMID:
24515335
16.

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y, Emadi A, Sausville EA, Baer MR.

Leuk Lymphoma. 2014 Jul;55(7):1533-7. doi: 10.3109/10428194.2013.856425. Epub 2014 Feb 4.

PMID:
24144313
17.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
18.

Schistocytes, echinocytes, iron deficiency anemia, and thrombocytopenia - hematologic manifestations of splenic angiosarcoma.

Rosenblatt P, Koka R, Chen Q, Papadimitriou JC, Sausville EA, Emadi A.

Arch Iran Med. 2013 Oct;16(10):602-5. doi: 0131610/AIM.0011.

19.

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Papadopoulos KP, Burris HA 3rd, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE Jr, Wang Z, Lee S, Jones SF, Infante JR.

Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8. doi: 10.1007/s00280-013-2267-x. Epub 2013 Aug 25.

20.

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.

Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):897-908. doi: 10.1007/s00280-013-2249-z. Epub 2013 Aug 15.

21.

Unbalanced 11;18 translocation in an acute erythroid leukemia after radioactive iodine therapy.

Trikalinos NA, Chen Q, Ning Y, Sausville EA, Baer MR.

Cancer Genet. 2013 Jun;206(6):252-5. doi: 10.1016/j.cancergen.2013.06.003. Epub 2013 Jul 18.

PMID:
23871646
22.

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.

LoRusso P, Venkatakrishnan K, Chiorean EG, Noe D, Wu JT, Sankoh S, Corvez M, Sausville EA.

Invest New Drugs. 2014 Feb;32(1):160-70. doi: 10.1007/s10637-013-9988-x. Epub 2013 Jul 2.

23.

Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.

Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA.

Cancer Chemother Pharmacol. 2013 Aug;72(2):417-27.

24.

A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.

Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L, Sausville EA.

Mol Cancer Ther. 2013 May;12(5):809-18. doi: 10.1158/1535-7163.MCT-12-0710. Epub 2013 Feb 26.

25.

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA.

Invest New Drugs. 2013 Oct;31(5):1217-27. doi: 10.1007/s10637-013-9937-8. Epub 2013 Feb 27.

26.

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.

Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Klein PJ, Leamon CP, Messmann RA, Sausville EA.

J Clin Oncol. 2012 Nov 10;30(32):4011-6. doi: 10.1200/JCO.2011.41.4946. Epub 2012 Oct 1.

27.

Promises from trametinib in RAF active tumors.

Sausville EA.

N Engl J Med. 2012 Jul 12;367(2):171-2. doi: 10.1056/NEJMe1205654. Epub 2012 Jun 4. No abstract available.

PMID:
22663012
28.

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.

Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR.

Leuk Lymphoma. 2011 Jul;52(7):1211-4. doi: 10.3109/10428194.2011.566950. Epub 2011 May 3.

PMID:
21534873
29.

Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.

Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, Nelson M, Westrick E, Parker N, Bruna K, Vetzel M, Gehrke M, Nicoson JS, Messmann RA, LoRusso PM, Sausville EA.

J Pharmacol Exp Ther. 2011 Feb;336(2):336-43. doi: 10.1124/jpet.110.175109. Epub 2010 Oct 26.

30.

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM.

Clin Cancer Res. 2010 Jul 15;16(14):3795-804. doi: 10.1158/1078-0432.CCR-10-0503. Epub 2010 Jun 4.

31.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.

32.

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.

Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P.

J Clin Pharmacol. 2009 Dec;49(12):1467-76. doi: 10.1177/0091270009339740. Epub 2009 Oct 16.

33.

Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.

Borgman MP, Aras O, Geyser-Stoops S, Sausville EA, Ghandehari H.

Mol Pharm. 2009 Nov-Dec;6(6):1836-47. doi: 10.1021/mp900134c.

34.

Mitochondrial function as an emerging 'target of interest' for cancer treatment.

Sausville EA.

Curr Opin Investig Drugs. 2009 Jun;10(6):523-5. No abstract available.

PMID:
19513940
35.

Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.

Borgman MP, Ray A, Kolhatkar RB, Sausville EA, Burger AM, Ghandehari H.

Pharm Res. 2009 Jun;26(6):1407-18. doi: 10.1007/s11095-009-9851-0. Epub 2009 Feb 19.

36.

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.

Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.

Clin Cancer Res. 2009 Mar 1;15(5):1708-20. doi: 10.1158/1078-0432.CCR-08-1543. Epub 2009 Feb 17.

37.

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.

Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD.

Clin Cancer Res. 2009 Mar 1;15(5):1698-707. doi: 10.1158/1078-0432.CCR-08-1587. Epub 2009 Feb 17.

38.

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.

Strome SE, Sausville EA, Mann D.

Oncologist. 2007 Sep;12(9):1084-95. Review.

39.

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.

Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH.

J Biol Chem. 2007 Mar 23;282(12):8860-72. Epub 2007 Jan 9.

40.

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE.

Blood. 2007 Apr 1;109(7):2781-90.

41.
42.

Respecting cancer drug transportability: a basis for successful lead selection.

Sausville EA.

J Natl Cancer Inst. 2006 Aug 16;98(16):1098-9. No abstract available.

PMID:
16912257
43.

The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S.

Cancer Cell. 2006 Aug;10(2):133-43.

44.

Contributions of human tumor xenografts to anticancer drug development.

Sausville EA, Burger AM.

Cancer Res. 2006 Apr 1;66(7):3351-4, discussion 3354. Review.

45.

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, Venitz J, Figg WD, Sparreboom A.

Invest New Drugs. 2006 Sep;24(5):367-75.

PMID:
16583304
46.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.

47.

Preclinical modeling of combination treatments: fantasy or requirement?

Decker S, Sausville EA.

Ann N Y Acad Sci. 2005 Nov;1059:61-9. Review.

PMID:
16382044
48.

Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.

Wallqvist A, Connelly J, Sausville EA, Covell DG, Monks A.

Mol Pharmacol. 2006 Mar;69(3):737-48. Epub 2005 Dec 6.

49.

Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.

Brantley E, Antony S, Kohlhagen G, Meng L, Agama K, Stinson SF, Sausville EA, Pommier Y.

Cancer Chemother Pharmacol. 2006 Jul;58(1):62-72. Epub 2005 Dec 6.

PMID:
16331501
50.

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.

Cancer Res. 2005 Nov 1;65(21):9953-61.

Supplemental Content

Loading ...
Support Center